Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Status: Completed

Conditions: Renal Cell Carcinoma Stage IV

Treatments: Behavioral: Patient Post Intervention Survey; Behavioral: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; Behavioral: Weekly Quiz; Behavioral: eHEALS digital literacy test; Other: mHealth Smart Phone Application

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05579847

MCC-21569

Details and patient eligibility

About

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Stage IV Renal Cell Carcinoma
• Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
• Estimated survival of 6 months or more
• Able to read and speak English

Exclusion criteria

• Unable to read or speak English
• Enrolled in another clinical trial

Trial design

20 participants in 1 patient group

Study Participants

Description:

Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.

Treatment:

Other: mHealth Smart Phone Application

Behavioral: eHEALS digital literacy test

Behavioral: Weekly Quiz

Behavioral: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

Behavioral: Patient Post Intervention Survey